

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 3


Amendments to the Claims:

This listing of claim will replace all prior versions, and listings of claims in the specification:

Listing of Claims:


Claims 1-39. (canceled)

40. (new) Compounds of the general formula




(I)


wherein



is a group of one of the formulae




(a1)




(a2)




is a group of one of the formulae




A1



A2



A3




A4




A5




A6




A7




A8




A9




A10




A11




A12




A13




A14




A15




A16




A17




A18


























A19




Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 6




41
Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 7



Applicant: Zumbrunn et al.
 Application No.: Unassigned
 Filing Date: Herewith
 Docket No.: 753-54 PCT/US
 Page 8



-B-CO- is Asn; Cys; Gln; His; Met; Phe; Pro; Ser; Thr; Trp; Tyr; Sar; 4AmPhe; 3AmPhe; 2AmPhe; Phe(mC(NH₂)=NH; Phe(pC(NH₂)=NH; Phe(mNHC (NH₂)=NH; Phe(pNHC (NH₂)=NH; Phg; Cha; C₄al; C₅al; 2-Nal; 1-Nal; 4Cl-Phe; 3Cl-Phe; 2Cl-Phe; 3,4Cl₂Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tza; Mso; Y(Bzl); Bip; S(Bzl); T(Bzl); hCha; hCys; hSer; hPhe; Bpa; Pip; OctG; MePhe; MeNle; MeAla; MeIle; MeVal; or MeLeu; or B is a group, having (L)- configuration, of formula



A8''

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 9

wherein R^{20} is H; or lower alkyl; and R^{64} is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R^1 is hydrogen or lower alkyl;

R^2 is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy); R^3 is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$).

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 10

; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);
-(CH₂)_oN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl);
-(CH₂)_oCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)_oCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);
-(CH₂)_oPO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)_oSO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy).
R⁴ is H; lower alkyl; lower alkenyl; -(CH₂)_mOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl);
-(CH₂)_mSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);
-(CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are -(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);
-(CH₂)_mN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl);
-(CH₂)_oCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)_oCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);
-(CH₂)_oPO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)_oSO₂R⁶² (where R⁶² is

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 11

lower alkyl; or lower alkenyl); or $-(\text{CH}_2)_q\text{C}_6\text{H}_4\text{R}^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy).

R^5 is lower alkyl; lower alkenyl; $-(CH_2)_oOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_oSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $(CH_2)_oNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy).

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 12

together are

$-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_2-$;
 $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$;
 $-(CH_2)_2S(CH_2)_2-$; or
 $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or
 $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); R^7 is lower alkyl; lower alkenyl; $-(CH_2)_qOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_qSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_qNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_2-$;
 $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_qOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are
 $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_qNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_qN(R^{20})COR^{64}$ (where R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_qCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_qCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 13

-(CH₂)₂₋₆;- (CH₂)₂O(CH₂)₂;- (CH₂)₂S(CH₂)₂;- or
-(CH₂)₂NR⁵⁷(CH₂)₂;- where R⁵⁷ is H; or lower alkyl); -(CH₂)₂PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)₂SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or
-(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);
R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; -(CH₂)₀OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); -(CH₂)₀SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)₀NR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆;-
-(CH₂)₂O(CH₂)₂;-; -(CH₂)₂S(CH₂)₂;- or -(CH₂)₂NR⁵⁷(CH₂)₂;- where R⁵⁷ is H; or lower alkyl);
-(CH₂)₀OCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are -(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂;-; -(CH₂)₂S(CH₂)₂;- or -(CH₂)₂NR⁵⁷(CH₂)₂;- where R⁵⁷ is H; or lower alkyl); -(CH₂)₀NR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆;-
-(CH₂)₂O(CH₂)₂;-; -(CH₂)₂S(CH₂)₂;- or -(CH₂)₂NR⁵⁷(CH₂)₂;- where R⁵⁷ is H; or lower alkyl);
-(CH₂)₀N(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl);
-(CH₂)₀COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)₀CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆;-
-(CH₂)₂O(CH₂)₂;-; -(CH₂)₂S(CH₂)₂;- or -(CH₂)₂NR⁵⁷(CH₂)₂;- where R⁵⁷ is H; or lower alkyl);
-(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);
R⁹ is lower alkyl; lower alkenyl; -(CH₂)₀OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl);
-(CH₂)₀SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)₀NR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆;-
-(CH₂)₂O(CH₂)₂;-
-(CH₂)₂S(CH₂)₂;- or -(CH₂)₂NR⁵⁷(CH₂)₂;- where R⁵⁷ is H; or lower alkyl); -(CH₂)₀OCONR³³R⁷⁵

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 14

(where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are

-(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_oN(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -(CH₂)_oCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)_oCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_oPO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)_oSO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy); R¹⁰ is lower alkyl; lower alkenyl; -(CH₂)_oOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); -(CH₂)_oSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)_oNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_oOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_oNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_oN(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl);

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 15

$-(CH_2)_nCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_nCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_nPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_nSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); R^{11} is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mN(R^{20})COR^{64}$ (where R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_nCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_nCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_nPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_nSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); R^{12} is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl);

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 16

$-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_mNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6}$;

$-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_mN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_rCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_rCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6}$;

$-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_rPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy):

R^{13} is lower alkyl; lower alkenyl; $-(CH_2)_qOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_qSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_qNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6}$); $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_qOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6}$); $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_qNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6}$); $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_qN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_rCOOR^{57}$ (where

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 17

R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_qCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_2PO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_2SO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy);

R^{14} is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl); R^{33} is H; or lower alkyl; or lower alkenyl is R^{82} ; H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$;

$-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_mN(R^{20})COR^{64}$ (where: R^{20} is H; lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$); $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy);

R^{15} is lower alkyl; lower alkenyl; $-(CH_2)_oOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_oSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_oNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$;

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 18

-(CH₂)₂O(CH₂)₂-;
-(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀OCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are -(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀NR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-;
-(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀N(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -NR²⁰COlower alkyl (R²⁰=H; or lower alkyl); being particularly favoured; -(CH₂)₀COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)₀CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl, or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl);
-(CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or (CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);
R¹⁶ is lower alkyl; lower alkenyl; -(CH₂)₀OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl);
-(CH₂)₀SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)₀NR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂O(CH₂)₂-;
-(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀OCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are -(CH₂)₂₋₆;-;
-(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀NR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆-;

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 19

-(CH₂)₂O(CH₂)₂-;
-(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀N(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -(CH₂)₀COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)₀CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or
-(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or
-(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy); and R¹⁷ is lower alkyl; lower alkenyl; -(CH₂)_qOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl);
-(CH₂)_qSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)_qNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆-;
-(CH₂)₂O(CH₂)₂-;
-(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_qOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are
-(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_qNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆-;
-(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);
-(CH₂)_qN(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl);
-(CH₂)₀COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)₀CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are
-(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl);
-(CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);
R²⁰ is H; or lower alkyl;

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 20

R¹⁸ is lower alkyl;

R^{19} is lower alkyl; lower alkenyl; $-(CH_2)_pOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_pSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_pNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_pOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_pNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_pN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $(CH_2)_pCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $(CH_2)_pCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; or lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_pPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_pSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $(CH_2)_pC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy);

alkyl);

$-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl, or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); R^{22} is lower alkyl; lower alkenyl; $-(CH_2)_oOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_oSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_oNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_oOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl, or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl);

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 22

together are

$-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-NR^{20}CO$ lower alkyl ($R^{20}=H$; or lower alkyl) being particularly favoured; $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl, or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); R^{25} is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_mN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl);

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 24

$-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy);

R^{26} is H; lower alkyl; lower alkenyl; $-(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or

$-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_mNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_mN(R^{20})COR^{64}$ (where: R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl; or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl);

$-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); or, alternatively, R^{25} and R^{26} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{34}(CH_2)_{2-}$;

R^{27} is H; lower alkyl; lower alkenyl; $-(CH_2)_oOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_oSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_oNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 25

together are

$-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_{2-}$;
 $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl, or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$;
 $-(CH_2)_2S(CH_2)_{2-}$; or
 $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oPO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $-(CH_2)_oSO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or
 $-(CH_2)_qC_6H_4R^8$ (where R^8 is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy); R^{28} is lower alkyl; lower alkenyl; $-(CH_2)_oOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $-(CH_2)_oSR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $-(CH_2)_oNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_{2-}$;
 $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are
 $-(CH_2)_{2-6-}$; $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oNR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkenyl; R^{82} is H; or lower alkyl; or R^{33} and R^{82} taken together are $-(CH_2)_{2-6-}$;
 $-(CH_2)_2O(CH_2)_{2-}$; $-(CH_2)_2S(CH_2)_{2-}$; or $-(CH_2)_2NR^{57}(CH_2)_{2-}$; where R^{57} is H; or lower alkyl); $-(CH_2)_oN(R^{20})COR^{64}$ (where R^{20} is H; or lower alkyl; R^{64} is lower alkyl; or lower alkenyl); $-(CH_2)_oCOOR^{57}$ (where R^{57} is lower alkyl; or lower alkenyl); $-(CH_2)_oCONR^{58}R^{59}$ (where R^{58} is lower alkyl, or lower alkenyl; and R^{59} is H; lower alkyl; or R^{58} and R^{59} taken together are

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 26

-(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl; -(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy); and R²⁹ is lower alkyl; lower alkenyl; -(CH₂)₀OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); -(CH₂)₀SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)₀NR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀OCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀NR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀N(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -NR²⁰COlower-alkyl (R²⁰=H; or lower alkyl) being particularly favoured; -(CH₂)₀COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)₀CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl, or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy); Z and Z¹ are chains of n and, respectively, n' α -amino acid residues whereby either n is 4 and n' is 6 or n is 5 and n' is 7, the positions of said amino acid residues in said chain Z being counted starting from the N-terminal amino acid and the positions of said amino acid residues in said chain Z¹ being counted starting from the C-terminal amino acid, whereby these amino acid residues are, depending on their position in the chains, Gly, or Pro, or of one of the types

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 27

C: $-\text{NR}^{20}\text{CH}(\text{R}^{72})\text{CO}-$;

D: $-\text{NR}^{20}\text{CH}(\text{R}^{73})\text{CO}-$;

E: $-\text{NR}^{20}\text{CH}(\text{R}^{74})\text{CO}-$;

F: $-\text{NR}^{20}\text{CH}(\text{R}^{84})\text{CO}-$; and

H: $-\text{NR}^{20}-\text{CH}(\text{CO}-)-(\text{CH}_2)_{4-7}-\text{CH}(\text{CO}-)-\text{NR}^{20}-$;
 $-\text{NR}^{20}-\text{CH}(\text{CO}-)-(\text{CH}_2)_p\text{SS}(\text{CH}_2)_p-\text{CH}(\text{CO}-)-\text{NR}^{20}-$;
 $-\text{NR}^{20}-\text{CH}(\text{CO}-)-(-(\text{CH}_2)_p\text{NR}^{20}\text{CO}(\text{CH}_2)_p-\text{CH}(\text{CO}-)-\text{NR}^{20}-$;
 $-\text{NR}^{20}-\text{CH}(\text{CO}-)-(-(\text{CH}_2)_p\text{NR}^{20}\text{CONR}^{20}(\text{CH}_2)_p-\text{CH}(\text{CO}-)-\text{NR}^{20}-$; and

I: $-\text{NR}^{86}\text{CH}_2\text{CO}-$;

R^{71} is lower alkenyl; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OR}^{75}$; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{SR}^{75}$;
 $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OCONR}^{33}\text{R}^{75}$;
 $-(\text{CH}_2)_o(\text{CHR}^{61})_s\text{COOR}^{75}$; $-(\text{CH}_2)_p\text{CONR}^{58}\text{R}^{59}$; $-(\text{CH}_2)_p\text{PO}(\text{OR}^{62})_2$; $-(\text{CH}_2)_p\text{SO}_2\text{R}^{62}$; or
 $-(\text{CH}_2)_o-\text{C}_6\text{R}^{67}\text{R}^{68}\text{R}^{69}\text{R}^{70}\text{R}^{76}$;

R^{72} is H, lower alkyl; lower alkenyl; $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{OR}^{85}$; or $-(\text{CH}_2)_p(\text{CHR}^{61})_s\text{SR}^{85}$;

R^{73} is $-(\text{CH}_2)_o\text{R}^{77}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_o\text{R}^{77}$; $-(\text{CH}_2)_r\text{S}(\text{CH}_2)_o\text{R}^{77}$; or $-(\text{CH}_2)_r\text{NR}^{20}(\text{CH}_2)_o\text{R}^{77}$;

R^{74} is $-(\text{CH}_2)_p\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{NR}^{77}\text{R}^{80}$; $-(\text{CH}_2)_p\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}(=\text{NOR}^{50})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{C}(=\text{NNR}^{78}\text{R}^{79})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{NR}^{80}\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{N}=\text{C}(\text{NR}^{78}\text{R}^{80})\text{NR}^{79}\text{R}^{80}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{77}\text{R}^{80}$;
 $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NOR}^{50})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NNR}^{78}\text{R}^{79})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{80}\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_p\text{C}_6\text{H}_4\text{N}=\text{C}(\text{NR}^{78}\text{R}^{80})\text{NR}^{79}\text{R}^{80}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_m\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_m\text{NR}^{77}\text{R}^{80}$;
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}(=\text{NOR}^{50})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}(=\text{NNR}^{78}\text{R}^{79})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_m\text{NR}^{80}\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_m\text{N}=\text{C}(\text{NR}^{78}\text{R}^{80})\text{NR}^{79}\text{R}^{80}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}_6\text{H}_4\text{CNR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NOR}^{50})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}_6\text{H}_4\text{C}(=\text{NNR}^{78}\text{R}^{79})\text{NR}^{78}\text{R}^{79}$;
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_p\text{C}_6\text{H}_4\text{NR}^{80}\text{C}(=\text{NR}^{80})\text{NR}^{78}\text{R}^{79}$; $-(\text{CH}_2)_r\text{S}(\text{CH}_2)_m\text{NR}^{78}\text{R}^{79}$;

Applicant: Zumbrunn et al.
 Application No.: Unassigned
 Filing Date: Herewith
 Docket No.: 753-54 PCT/US
 Page 28

-(CH₂)_rS(CH₂)_mNR⁷⁷R⁸⁰; -(CH₂)_rS(CH₂)_pC(=NR⁸⁰)NR⁷⁸R⁷⁹;
 -(CH₂)_rS(CH₂)_pC(=NOR⁵⁰)NR⁷⁸R⁷⁹; -(CH₂)_rS(CH₂)_pC(=NNR⁷⁸R⁷⁹)NR⁷⁸R⁷⁹;
 -(CH₂)_rS(CH₂)_mNR⁸⁰C(=NR⁸⁰)NR⁷⁸R⁷⁹; -(CH₂)_rS(CH₂)_mN=C(NR⁷⁸R⁸⁰)NR⁷⁹R⁸⁰;
 -(CH₂)_rS(CH₂)_pC₆H₄CNR⁷⁸R⁷⁹; -(CH₂)_rS(CH₂)_pC₆H₄C(=NR⁸⁰)NR⁷⁸R⁷⁹;
 -(CH₂)_rS(CH₂)_pC₆H₄C(=NOR⁵⁰)NR⁷⁸R⁷⁹; -(CH₂)_rS(CH₂)_pC₆H₄C(=NNR⁷⁸R⁷⁹)NR⁷⁸R⁷⁹;
 -(CH₂)_rS(CH₂)_pC₆H₄NR⁸⁰C(=NR⁸⁰)NR⁷⁸R⁷⁹; -(CH₂)_pNR⁸⁰COR⁶⁴; -(CH₂)_pNR⁸⁰COR⁷⁷;
 -(CH₂)_pNR⁸⁰CONR⁷⁸R⁷⁹; or -(CH₂)_pC₆H₄NR⁸⁰CONR⁷⁸R⁷⁹;


R⁷⁵ is lower alkyl; lower alkenyl; or aryl-lower alkyl;

R³³ and R⁷⁵ taken together can form: -(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂;-; -(CH₂)₂S(CH₂)₂;-; or
 -(CH₂)₂NR⁵⁷(CH₂)₂;-;


R⁷⁵ and R⁸² taken together can form: -(CH₂)₂₋₆;-; -(CH₂)₂O(CH₂)₂;-; -(CH₂)₂S(CH₂)₂;-; or
 -(CH₂)₂NR⁵⁷(CH₂)₂;-;

R⁷⁶ is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH₂)_oOR⁷²; -(CH₂)_oSR⁷²;
 -(CH₂)_oNR³³R³⁴; -(CH₂)_oOCONR³³R⁷⁵; -(CH₂)_oNR²⁰CONR³³R⁸²;
 -(CH₂)_oCOOR⁷⁵; -(CH₂)_oCONR⁵⁸R⁵⁹; -(CH₂)_oPO(OR⁶⁰)₂; -(CH₂)_pSO₂R⁶²; or
 -(CH₂)_oCOR⁶⁴;


R⁷⁷ is -C₆R⁶⁷R⁶⁸R⁶⁹R⁷⁰R⁷⁶; or a heteroaryl group of one of the formulae




H1




H2




H3




H4




H5




H6




H7



H8




H9




H10

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 29



Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 30



R⁷⁸ is H; lower alkyl; aryl; or aryl-lower alkyl;

R⁷⁸ and R⁸² taken together can form: -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-;

R⁷⁹ is H; lower alkyl; aryl; or aryl-lower alkyl; or

R⁷⁸ and R⁷⁹, taken together, can be -(CH₂)₂₋₇-; -(CH₂)₂O(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-;

R⁸⁰ is H; or lower alkyl;

R⁸¹ is H; lower alkyl; or aryl-lower alkyl;

R⁸² is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;

R³³ and R⁸² taken together can form: -(CH₂)₂₋₆-; -(CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-;

R⁸³ is H; lower alkyl; aryl; or -NR⁷⁸R⁷⁹;

R⁸⁴ is -(CH₂)_pCONR⁷⁸R⁷⁹; -(CH₂)_pNR⁸⁰CONR⁷⁸R⁷⁹; -(CH₂)_pC₆H₄CONR⁷⁸R⁷⁹; or -(CH₂)_pC₆H₄NR⁸⁰CONR⁷⁸R⁷⁹;

R⁸⁵ is lower alkyl; or lower alkenyl;

R⁸⁶ is R⁷⁴; -[(CH₂)_u-X]_t-(CH₂)_vNR⁷⁸R⁷⁹; -[(CH₂)_u-X]_t-(CH₂)_v-C(=NR⁸⁰)NR⁷⁸R⁷⁹; X is -O-, -NR²⁰-, -S-, -OCOO-, u is 1-3, t is 1-6, v is 1-3;

with the proviso that in said chains Z and Z' of n and , respectively, n' α -amino acid residues

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 31

- if n is 4 and n' is 6, the amino acid residues in positions 1 to 4 of Z and in positions 1' to 6' of Z¹ are:
 - P1: of type C or of type D or of type E or of type F, or the residue is Pro;
 - P2: of type E or of type F;
 - P3: of type F, or the residue is Pro;
 - P4: of type E;
- P1': of type C or of type D or of type E or of type F, or the residue is Gly;
- P2': of type D or of type C;
- P3': of type F or the residue is Pro;
- P4': of type D or of type C;
- P5': of type E, or of type F or the residue is Pro; and
- P6': of type E or of type F, or the residue is Pro; or
- P3 and P3', taken together, can form a group of type H;

and

- if n is 5 and n' is 7, the amino acid residues in positions 1 to 5 of Z and in positions 1' to 7' of Z¹ are:
 - P1: of type C or of type D or of type E or of type F, or the residue is Pro;
 - P2: of type E or of type F;
 - P3: of type F, or the residue is Pro;
 - P4: of type F;
 - P5: of type E


- P1': of type C or of type D or of type E or of type F, or the residue is Pro;
- P2': of type F;
- P3': of type D or the residue is Pro;
- P4': of type E or of type F;
- P5': of type D, or the residue is Pro;
- P6': of type E or of type F, or the residue is Pro; and
- P7': of type E or of type I, or the residue is Gly; or

- P2 and P2' and/or P4 and P4', taken together, can form a group of type H;
at P7' also D-isomers being possible,

and pharmaceutically acceptable salts thereof.

41. (new) Compounds according to claim 40, wherein A is a group of one of the formulae A5 (with R² being H); A8; A22; A25; A38 (with R² being H); A42; and A50.

42. (new) Compounds according to claim 41, wherein A is a group of formula



A8'

wherein R²⁰ is H or lower alkyl; and R⁶⁴ is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl.

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 33

43. (new) Compounds according to claim 42, wherein R⁶⁴ is n-hexyl; n-heptyl; 4-(phenyl)benzyl; diphenylmethyl; 3-amino-propyl; 5-amino-pentyl; methyl; ethyl; isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3-indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.

44. (new) Compounds according to claim 40, wherein R²³, R²⁴ and R²⁹ are -NR²⁰-CO-lower alkyl where R²⁰ is H; or lower alkyl.

45. (new) Compounds according to claim 40, wherein A is a group of one of the formulae A74 (with R²² being H); a75; A76; A77 (with R²² being H); A78; and A79.

46. (new) Compounds according to claim 44, wherein A is a group, of one of the formulae A74 (with R²² being H); a75; A76; A77 (with R²² being H); A78; and A79.

47. (new) Compounds according to claim 40, wherein B is a group, having (L)-configuration, of formula A8" as shown in claim 1 in which R⁶⁴ is n-hexyl; n-heptyl; 4-(phenyl)benzyl; diphenylmethyl; 3-amino-propyl; 5-amino-pentyl; methyl; ethyl; isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3-indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.

48. (new) Compounds according to claim 40, wherein n is 4, n' is 6 and the α -amino acid residues in positions 1 to 4 of the chain Z and 1'-6' in chain Z¹ are:

- P1: of type D or of type E or of type F, or the residue is Pro;
- P2: of type E or of type F;
- P3: of type F, or the residue is Pro;
- P4: of type E;

- P1': of type E or of type F, or the residue is Gly;

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 34

- P2': of type D;
- P3': of type F or the residue is Pro;
- P4': of type D;
- P5': of type E, or of type F or the residue is Pro; and
- P6': of type E or of type F, or the residue is Pro; or
- P3 and P3', taken together, can form a group of type H

49. (new) Compounds according to claim 40, wherein n is 5, n' is 7 and the α -amino acid residues in positions 1 to 5 of the chain Z and 1'-7' in chain Z¹ are:

- P1: of type D or of type E or of type F, or the residue is Pro;
- P2: of type E or of type F;
- P3: of type F, or the residue is Pro;
- P4: of type F;
- P5: of type E

- P1': of type D or of type E or of type F, or the residue is Pro;
- P2': of type F;
- P3': of type D or the residue is Pro;
- P4': of type F;
- P5': of type D, or the residue is Pro;
- P6': of type E or of type F, or the residue is Pro; and
- P7': of type E or of type I, or the residue is Gly; or
- P2 and P2' and/or P4 and P4', taken together, can form a group of type H;
at P7`also D-isomers being possible.

50. (new) Compounds according to claim 48, wherein the α -amino acid residues in positions 1 to 4 of the chain Z and the α -amino acid residues in positions 1' to 6' chain Z¹ are:

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 35

- P1: Tyr, or Arg;
- P2: Cit, or Arg;
- P3: Cys;
- P4: Arg-NH₂;
- P1': Lys, or Arg;
- P2': Tyr;
- P3': Cys;
- P4': 2-Nal;
- P5': Arg;
- P6': Arg; and

Cys at P3 and P3' can form a disulfide bridge.

51. (new) Compounds according to claim 49, wherein the α -amino acid residues in positions 1 to 5 of the chain Z and the α -amino acid residues in positions 1' to 7' chain Z¹ are:

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg, or Arg-NH₂;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': 2-Nal, Trp, F(pNH₂), or W(6-Cl);
- P6': Arg;
- P7': ^DArg, Arg, Ac-Arg, iPr-Arg, (EA)G, (PrA)G, (BA)G, (EGU)G, (PrGU)G,

or

(BGU)G; and

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 36

Cys at P4 and P4' can form a disulfide bridge.

52. (new) A compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg-NH₂;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': 2-Nal;
- P6': Arg; and
- P7': Arg;

Cys at P4' and P4 forming a disulfide bridge.

53. A compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg-NH₂;
- P1': Lys;

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 37

- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': 2-Nal;
- P6': Arg; and
- P7': Ac-Arg;

Cys at P4' and P4 forming a disulfide bridge.

54. (new) A compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg-NH₂;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': 2-Nal
- P6': Arg; and
- P7': ^DArg;

Cys at P4' and P4 forming a disulfide bridge.

55. (new) A compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 38

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg-NH₂;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': Phe(pNH₂);
- P6': Arg; and
- P7': Arg;

Cys at P4' and P4 forming a disulfide bridge.

56. (new) A compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg-NH₂;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': 2-Nal;
- P6': Arg; and

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 39

- P7': (PrA)G;
Cys at P4' and P4 forming a disulfide bridge.

57. (new) A compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': 2-Nal;
- P6': Arg; and
P7': Arg;

Cys at P4' and P4 forming a disulfide bridge.

58. (new) Enantiomers of the compounds of formulae I as defined in claim 40.

59. (new) Compounds according to claim 40, for use as therapeutically active substances.


60. (new) Compounds according to claim 59, for use as CXCR4 antagonists.

61. (new) A pharmaceutical composition containing a compound according claim 40 and a pharmaceutically inert carrier.


62. (new) Compositions according to claim 61 in a form suitable for a mode of administration selected from the group consisting of oral, topical, transdermal, injection, buccal, transmucosal, pulmonary and inhalation.
63. (new) Compositions according to claim 61 in a form selected from the group consisting of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
64. (new) Compositions according to claim 62 in form selected from the group consisting of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
65. (new) A method for treating and/or preventing a disorder selected from the group consisting of HIV infections, cancer and inflammatory disorders, the method comprising:
administering to a subject in need thereof a compound according to claim 40.
66. (new) A process for the manufacture of compounds according to any one of claim 40, which process comprises
 - (a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 4 of Z if n is 4 or in position 5 of Z if n is 5, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
 - (b) removing the N-protecting group from the product thus obtained;
 - (c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in Z of the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 41

- (d) removing the N-protecting group from the product thus obtained;
- (e) repeating steps (c) and (d) until the N-terminal amino acid residue of Z has been introduced;
- (f) coupling the product thus obtained with a compound of the general formula



wherein



is as defined in claim 1 and X is an N-protecting group; or, alternatively,

(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula



wherein B and A are as defined in claim 1, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (fb) removing the N-protecting group from the product thus obtained; and
- (fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (g) removing the N-protecting group from the product obtained in step (f) or (fc);

- (h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 1 of Z^1 , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (i) removing the N-protecting group from the product thus obtained;
- (j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 1 of Z^1 , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (k) removing the N-protecting group from the product thus obtained;
- (l) repeating steps (j) and (k) until all amino acid residues of Z^1 have been introduced;
- (m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (n) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (o) detaching the product thus obtained from the solid support and removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and
- (p) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt..

67. (new) A process according to claim 66, but wherein an amino acid residue of type I is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula H_2NR^{86} which, if necessary, is appropriately protected.

68. (new) A process according to claim 67, wherein the leaving group in said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.

Applicant: Zumbrunn et al.
Application No.: Unassigned
Filing Date: Herewith
Docket No.: 753-54 PCT/US
Page 43

69. (new) A modification of the process according to claim 66 for the manufacture of compounds according to claim 56 in which enantiomers of all chiral starting materials are used.
70. (new) A modification of the process according to claim 67 for the manufacture of compounds according to claim 56 in which enantiomers of all chiral starting materials are used.